Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors. Zhang C, Wang H. Lung Cancer 2021;154:221-223.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhang C, Wang H. Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors. Lung Cancer 2021;154:221-223.
PMID: 33637343